Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Incyte (NASDAQ: INCY) reported stronger-than-expected second-quarter results and upwardly revised its full-year sales guidance, leading several analysts to raise their price targets. The biopharmaceutical company exceeded earnings and revenue estimates, driven by broad-based sales growth and pipeline progress. Despite the improved outlook, Incyte's updated guidance remains below the current analyst consensus.